Aquestive Therapeutics Announces 2023 Financial Outcomes and Updates on Business Progress

Aquestive Therapeutics AQST, a pharmaceutical company specializing in the development of treatments for diseases requiring urgent medication, has disclosed its complete financial results for the fiscal year 2023. The firm reported generating revenue of $50.6 million. Despite the revenue, the company experienced a non-GAAP adjusted EBITDA loss amounting to $11.6 million for the year.

Gearing Up for Clinical and Regulatory Milestones

In addition to its financial results, Aquestive Therapeutics has reiterated its commitment to releasing topline pivotal clinical data for its Anaphylm™ (epinephrine) Sublingual Film. The pharmaceutical company has scheduled this important release for March 2024. The announcement has been keenly anticipated as it may potentially offer a new and convenient treatment option for severe allergic reactions.

The firm has also confirmed continuity in its trajectory towards the awaited decision by the US Food and Drug Administration (FDA) on Libervant™ (diazepam) Buccal Film. This product aims to provide a unique therapeutic solution for patients who require management of refractory epilepsy clusters.

Outlook and Forward-Looking Statements

The statements released by Aquestive contained forward-looking information based on current expectations. Given the inherent uncertainties in pharmaceutical research and development, it is important for stakeholders to remain aware that actual results could differ materially from what is projected. Such statements are predictive in nature, involve risks and uncertainties, and are based on the company's current beliefs and expectations about future events.

Investors and interested parties are encouraged to examine the results in light of these factors. Aquestive's reaffirmations mark significant milestones, potentially affecting the company's valuation and stakeholder confidence moving forward.

Aquestive, Revenue, EBITDA, Clinical, FDA, Pharmaceutical